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Abstract
The Established Status Epilepticus Treatment Trial was a blinded, comparative-
effectiveness study of fosphenytoin, levetiracetam, and valproic acid in benzodi-
azepine-refractory status epilepticus. The primary outcome was clinical seizure 
cessation and increased responsiveness without additional anticonvulsant medica-
tions. Weight-based dosing was capped at 75 kg. Hence, patients weighing >75 kg 
received a lower mg/kg dose. Logistic regression models were developed in 235 
adults to determine the association of weight (≤ or >75 kg, ≤ or >90 kg), sex, treat-
ment, and weight-normalized dose with the primary outcome and solely seizure ces-
sation. The primary outcome was achieved in 45.1% and 42.5% of those ≤75 kg and 
>75 kg, respectively. Using univariate analyses, the likelihood of success for those 
>75 kg (odds ratio [OR] = 0.9, 95% confidence interval [CI] = 0.54-1.51) or >90 kg 
(OR = 0.85, 95% CI = 0.42-1.66) was not statistically different compared with those 
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1 |  INTRODUCTION
The Established Status Epilepticus Treatment Trial (ESETT), 
which completed enrollment in January 2019, was a multi-
center, randomized, double-blind study to determine the best 
or worst second-line treatment among fosphenytoin (FOS), 
levetiracetam (LEV), and valproic acid (VPA) in patients 
with benzodiazepine-refractory status epilepticus (SE).1 The 
primary outcome of the study was cessation of SE at 60 min-
utes after the start of study drug infusion without use of ad-
ditional antiseizure medication, as determined by absence 
of clinically apparent seizures and improved consciousness. 
Subjects aged ≥2 years who failed first-line treatment with 
benzodiazepines and continued to have seizures were in-
cluded in this study.
To maintain the blind, the three drugs, FOS, LEV, and 
VPA, had to be administered at the same volume and in-
fusion rate even though the drugs had different mg/kg 
doses.2 The FOS product label recommends a maximum 
dose of FOS (prodrug of phenytoin) of 20  mg phenytoin 
equivalents (PE)/kg and that the rate of intravenous admin-
istration should not exceed 150 mg PE per minute due to 
cardiovascular risks associated with rapid injection.3 Given 
that the ESETT protocol fixed the infusion time at 10 min-
utes, dosing was capped at 1500  mg PE. As a result, all 
patients weighing ≥75 kg received the same capped dose 
of FOS (20 mg/kg, maximum = 1500 mg PE). Similarly, 
weight-based dosing was also capped at 75  kg for LEV 
(60  mg/kg, maximum = 4500  mg) and VPA (40  mg/kg, 
maximum = 3000 mg).
Patients weighing >75 kg received a lower mg/kg dose; 
thus, lower drug exposure would be expected given the phar-
macokinetic properties of these drugs. Therefore, we per-
formed a secondary analysis to assess whether the odds of 
treatment success were lower in patients weighing >75 kg as 
compared to those weighing ≤75 kg. Because a primary out-
come failure could be a result of one or more of the follow-
ing: (1) need for an additional antiseizure medication before 
60  minutes, (2) clinically apparent seizures at 60  minutes, 
and (3) lack of improvement in consciousness and response 
at 60  minutes, we also evaluated the association of weight 
and other predictors with clinical seizure cessation alone at 
60 minutes.
2 |  MATERIALS AND METHODS
ESETT was approved by institutional review boards for 
all participating institutions.1 Of the 478 patients enrolled 
in ESETT, 48.2% of adults and 0.9% of children weighed 
>75  kg. Because of the low number of children receiving 
a fixed dose and the possibility of differing response rates 
within children and adults, the analyses were limited to those 
≥18 years old (n = 249). Two patients were excluded because 
the study drug volume administered could not be determined. 
Among the 247 enrollments, 12 patients were enrolled more 
than once but only their first enrollments were used. Among 
the 235 unique adult patients, 132 (56.2%) failed the ESETT 
primary outcome. Of the 132 failures, 87 (65.9%) failed be-
cause they needed an additional antiseizure medication prior 
to 60 minutes, 10 (7.6%) failed due to clinically apparent sei-
zures at 60 minutes, and 35 (26.5%) failed because they did 
not show an improvement in responsiveness at 60 minutes 
despite clinical seizure cessation.
2.1 | ESETT primary outcome as the 
dependent variable
The ESETT primary outcome was expressed as binary 
(0 =  treatment failure, 1 =  treatment success) and used as 
the dependent variable for the following logistic regression 
models.
2.1.1 | Association of weight with primary  
outcome using univariate and multivariate  
analyses
Two logistic regression models were used to test the associa-
tion of weight, as a binary predictor, with primary outcome 
using weight cutoffs of 75 and 90 kg, respectively. A 90-kg 
≤75 kg or ≤90 kg, respectively. Similarly, other predictors were not significantly as-
sociated with primary outcome or clinical seizure cessation. Our findings suggest that 
doses, capped at 75 kg, likely resulted in concentrations greater than those needed for 
outcome. Studies that include drug concentrations and heavier individuals are needed 
to confirm these findings.
K E Y W O R D S
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cutoff was chosen to examine the association for higher 
weight individuals more rigorously. A logistic regression 
model also tested association of interactions of weight, sex, 
and treatment with the primary outcome. The model included 
treatment group (FOS, LEV, or VPA), sex (male or female), 
and weight as binary (≤ or >75 kg), with all the interaction 
terms (weight × treatment group × sex) as predictors of the 
primary outcome.
2.1.2 | Association of weight-normalized 
dose and sex with primary outcome
Separate logistic regression models were built for FOS, 
LEV, and VPA to test the association of weight-normalized 
dose in mg/kg as a continuous variable, sex (male or fe-
male), and the interaction of dose and sex with the ESETT 
primary outcome.
2.1.3 | Association of weight, sex, and 
treatment with clinical seizure cessation 
without additional antiseizure medication
A logistic regression model was used to test the association 
of weight and other predictors with clinical seizure cessation 
without additional antiseizure medication. Adult ESETT pa-
tients whose seizures were terminated but failed the primary 
outcome due to lack of improved responsiveness at 60 min-
utes (n = 35) were treated as successes. Clinical seizure ces-
sation, as binary (1 = success, 0 = failure), was used as the 
dependent variable for this analysis. A logistic model with 
weight, as a binary (≤ or >75 kg), sex (male or female), and 
treatment group (FOS, LEV, or VPA) with all interactions 
(weight × treatment group × sex) as predictors was used to 
test their association with clinical seizure cessation.
Significance was determined as an alpha level < .05. 
All the analyses were conducted using R (v3.6.1), RStudio 
(v1.2.5001), and SAS (v9.4).
3 |  RESULTS
3.1 | Distribution of weights
ESETT patients ≥18 years old weighed from 36 to 157 kg 
and weights were approximately normally distributed, with a 
mean of 76.7 kg and standard deviation of 18.9 kg (Figure 1). 
Of the 235 patients, 113 (48.1%) weighed >75  kg and re-
ceived the maximum doses. The overall success rate for the 
primary outcome was 45.1% in those ≤75 kg versus 42.5% 
in those >75 kg. Baseline characteristics of the adult popula-
tion by weight group (Table S1) show that male patients were 
more likely to weigh >75 kg (50% vs 66.4%), but all the other 
baseline characteristics were evenly distributed between the 
≤75-kg and >75-kg groups, respectively.
3.2 | Comparison of response rates between  
the weight-based dosing group and fixed dose  
group
The difference and 95% confidence interval (CI) in the re-
sponse rates for those ≤75  kg versus those >75  kg were 
3.1% (95% CI = −20.5% to 26.6%) for FOS, −1.2% (95% 
CI = −21.6% to 19.3%) for LEV, and 6.4% (95% CI = 
−16.1% to 28.9%) for VPA. None of the differences was 
statistically significant, as the 95% CI included 0 for each 
drug.
3.3 | Association of weight and other 
predictors with primary outcome using 
univariate and multivariate analyses
3.3.1 | Primary outcome versus weight
The odds of success were 10.1% lower (odds ratio = 0.9, 95% 
CI = 0.54-1.51) for those >75 kg compared to those ≤75 kg 
and 15.4% lower (odds ratio = 0.85, 95% CI = 0.42-1.66) 
F I G U R E  1  Distribution of 
Established Status Epilepticus Treatment 
Trial (ESETT) adult patient weights and the 
response to the treatment administered as 
treatment success (blue) or treatment failure 
(red)
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for those >90 kg compared to those ≤90 kg. These differ-
ences were not significant, as the 95% CIs for the odds ratios 
included 1. Similarly, there was no statistically significant as-
sociation with treatment success when sex, treatment group, 
and interaction of weight with sex and treatment group were 
included in the model (Table 1).
3.3.2 | Primary outcome versus sex and 
weight-normalized dose
When each drug was modeled separately, the weight-normal-
ized dose was not associated with success, nor was sex or the 
interaction of dose and sex (Table S2).
3.4 | Association of weight, sex, and 
treatment with clinical seizure cessation 
without additional antiseizure medication
A total of 138 (59%) patients did not have clinically ap-
parent seizures at 60  minutes without receiving additional 
antiseizure medication (regardless of whether they were re-
sponsive to verbal commands or noxious stimuli). As seen 
from Table 1, weight (≤ or >75 kg), sex (male or female), 
treatment group (FOS, LEV, or VPA), and all the interaction 
terms (weight × sex × treatment group) did not have a sig-
nificant association with clinical seizure cessation.
4 |  DISCUSSION
The results of these secondary analyses demonstrate that the 
differences in response rates between the fixed dosing regi-
men (>75 kg) and weight-based regimen (≤75 kg) were not 
significant when the study drugs were grouped together or 
analyzed separately. The logistic regression models using the 
ESETT primary outcome and clinical seizure cessation with-
out additional antiseizure medication as dependent variables 
also failed to find significant associations with weight, treat-
ment, sex, or weight-normalized dose.
Fixed dosing, which is commonly used in adults, results in 
lower doses per body weight in heavier individuals and poten-
tially lower drug concentrations for many drugs. Furthermore, 
if drug concentrations fall in the linear portion of the dose-re-
sponse curve, lower drug concentrations may result in re-
duced efficacy. In this study, although approximately half of 
the ESETT adult patients received the maximum dose, the re-
sponse rates between weight-based and fixed dosing regimen 
were similar. It is possible that weight or weight-normalized 
dose did not affect the primary outcome or clinical seizure 
cessation because the doses used in the trial resulted in drug 
concentrations greater than those needed for therapeutic out-
come even in patients weighing >75 kg. Although this may 
be true, other predictors, such as drug concentration, would 
have been a better metric to evaluate the differences between 
responders and nonresponders. We know that drug concen-
trations can be variable in individuals receiving an identical 
dose.4–6 There is also evidence that the pharmacokinetics 
of FOS, LEV, and VPA are altered in overweight and obese 
patients.7–10 In particular, patients with higher body fat will 
likely have greater volume of distribution. However, we were 
not able to investigate the effect of drug concentrations or body 
mass index (BMI), as sufficient information was not available. 
Furthermore, only 18 (7.7%) patients weighed >100 kg. Thus, 
differences in pharmacokinetics, if any, may not have been 
large enough to impact the outcome.
The ESETT primary outcome was a composite and in-
cluded absence of clinically apparent seizures and improved 
responsiveness at 60 minutes. It is possible that those who 
received higher doses were more likely to stop seizing but 
also more likely to have no improvement in responsiveness. 
To tease out the association of weight and other variables 
with clinical seizure cessation alone, we included those who 
failed the primary outcome only due to the lack of improved 
responsiveness at 60 minutes as successes, but found no sig-
nificant differences between fixed and weight-based dosing. 
Future studies of SE will likely include electroencephalogram 
T A B L E  1  Logistic regression models of the probability of success using weight, treatment, and sex with all interactions (weight ≤ 75 kg as 
reference group; n = 235)
Weight group Treatment Sex
Using primary outcome as dependent 
variable, aOR (95% CI)
Using clinical seizure cessation without 
additional antiseizure medication as 
dependent variable, aOR (95% CI)
>75 kg Fosphenytoin Male 0.71 (0.20-2.55) 0.56 (0.14-2.26)
>75 kg Fosphenytoin Female 1.13 (0.26-4.94) 1.16 (0.27-5.05)
>75 kg Levetiracetam Male 0.82 (0.26-2.56) 0.47 (0.15-1.49)
>75 kg Levetiracetam Female 1.70 (0.45-6.44) 1.08 (0.29-4.08)
>75 kg Valproic acid Male 0.83 (0.26-2.66) 0.72 (0.22-2.40)
>75 kg Valproic acid Female 0.64 (0.14-2.91) 0.49 (0.11-2.20)
aOR: Adjusted Odds Ratio
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as a part of outcome and allow us to better understand this 
subgroup.
A limitation of these analyses is the small number of pa-
tients in each treatment group (~40/drug) weighing >75 kg. 
The wide CIs for the difference in response rates suggest that a 
larger sample size would be needed to confirm these findings. 
While these were secondary analyses, the adaptive study de-
sign was powered adequately for the primary outcomes.
5 |  CONCLUSION
Weight-based dosing used in ESETT with a 75-kg cutoff 
does not appear to have an impact on the primary outcome 
or clinical seizure cessation. It is possible that the concentra-
tions attained were greater than those needed for therapeutic 
outcome. However, studies with larger sample size and ad-
ditional data (drug concentrations, BMI, etc) are required to 
confirm our findings. Future studies that measure drug con-
centrations would allow exploration of exposure-response 
instead of dose-response relationships.
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